How many patents cover Comirnaty (Pfizer-BioNTech COVID-19 vaccine)?
Public sources used here don’t provide a single, definitive count of “Comirnaty patents” globally. The number depends on what you count (e.g., vaccine drug substance vs. formulation, delivery systems, mRNA sequence patents, manufacturing-process patents, and improvements), which jurisdictions you include (US, EU, UK, etc.), and whether you count individual patent publications or whole patent families.
Why there isn’t one straightforward “total patent count” for Comirnaty
Patent holdings are usually tracked as families across many countries. A “Comirnaty-related” patent portfolio can expand quickly because the same invention is filed multiple ways (different claims, continuations, and national phase entries), and because companies also hold patents on production and quality-control methods used to manufacture the vaccine.
If you want a number, what should you specify?
To produce a meaningful patent count, you typically need to narrow the scope, such as:
- Which geography (USPTO only vs. worldwide / EPO / PatentScope).
- Which types of documents to count (granted patents only vs. published applications too).
- Which relevance filter to use (assignee = Pfizer / BioNTech, keywords like “Comirnaty,” or specific inventors/priority numbers).
What I can do next if you tell me your scope
Share which region and counting method you want (e.g., “US only, published applications,” or “worldwide patent families for Pfizer-BioNTech mRNA vaccine technology”), and I can help outline a search strategy and what a reported number would correspond to.
Sources
No sources were provided in the prompt with patent-count data for Comirnaty, so I can’t cite a specific number.